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Abstract Objective: Although elective cesarean sec-
tion (ECS) is the currently recommended modality for
delivering women infected with the human immuno-
deficiency virus (HIV), historical evidence suggests
that they are at higher risk of postoperative compli-
cations than noninfected women. Those risks have to
be carefully balanced against the presumed minimal
benefit of ECS, especially in the case of low viral load
and high CD4 counts. We therefore compared the
incidence and type of post-ECS complications in HIV-
infected women, most with low viral loads and high
CD4 cell counts, with those in matched noninfected
women treated by the same surgical teams. Study
design: A Swiss 8-center, prospective, matched case-
control study compared minor and major post-ECS
complication prevalence, hospital stay and confound-
ing factors (surgeon experience) between HIV-infected
and noninfected women. Results: Minor complications
in the 53 matched pairs were eightfold more frequent
overall in infected women. More frequent specific
minor complications were anemia, blood loss and
urinary tract infection. Yet the surgeons performing
ECS in infected women were more experienced.
Complications prolonged hospital stay in infected
women. Major complication rates did not significantly
differ between the groups. Conclusion: HIV-positive
women have a higher risk of post-ECS morbidity, even
with high CD4 counts and low viral load. Therefore,
the blanket recommendation of ECS in HIV-infected
women requires a review.
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Introduction
Interventions markedly reduce the vertical transmis-
sion rate of the human immunodeficiency virus (HIV):
by two-thirds (from 25 to 8%) with zidovudine given
orally during pregnancy, intravenously during delivery
and orally to the newborn for 6 weeks [1], and by half
with elective cesarean section (ECS) before rupture of
the membranes and labor onset. The two interventions
combined lower vertical transmission rates below 2%
[2], i.e., to the level achieved with successful highly
active antiretroviral treatment (HAART) during
pregnancy. The blanket recommendation for ECS in
HIV-infected women with a repeatedly undetectable
viral load (viral RNA < 20 copies/ml) is thus being
questioned especially in Europe, where ECS has been
the standard delivery modality in recent years. Its
benefits in such favorable cases appear marginal: many
ECS are required to prevent a single congenital HIV
infection. Maternal morbidity is higher than in vaginal
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delivery, and mortality can be increased up to sixfold
[3]. HIV-infected women may also be prone to in-
creased post-ECS complication rates based on their
underlying disease and/or immunosuppression [4-6].
Informed delivery modality counseling in women with
viral loads below the limit of detection requires accu-
rate quantification to balance the presumed minimal
benefit of ECS against its risks. We therefore com-
pared the incidence and type of post-ECS complica-
tions in HIV-infected women, most with low viral loads
and high CD4 cell counts, with those in matched
noninfected women treated by the same surgical teams.
Materials and methods
Pregnant HIV positive women, undergoing ECS in
eight hospitals were recruited by the Swiss Mother and
Child HIV Cohort Study (MoCHiV) [7]. Informed
written consent was obtained in all cases. The women
were matched at each center with HIV-negative
patients selected as the next to undergo ECS after the
infected index case. The noninclusion criteria were
emergency cesarean section, rupture of the mem-
branes, and multiple pregnancy. Matched-pair mater-
nal postpartum complications were recorded by
standardized case report forms, after hospital discharge
by the supervising obstetrical team using consensus
criteria for evaluating post-cesarean section morbidity
[8]. The questionnaires were then assessed by the au-
thors. The indication for ECS in infected women was
the prevention of vertical transmission; in noninfected
women the main indications were breech presentation
and maternal request. All sections were performed
before labor onset or membrane rupture, under spinal
anesthesia, using a transperitoneal approach and
transverse lower uterine segment incision. All infected
women were offered combined antiretroviral treat-
ment including a proteinase inhibitor and zidovudine
as one of two nucleoside analogues. In one center, all
patients received single-shot perioperative antibiotic
prophylaxis (2.2 g amoxicillin with clavulanic acid or,
for those allergic to penicillin, clindamycin 600 mg)
after cord clamping. All patients received low-molec-
ular weight heparin during hospitalization. The fol-
lowing complications were classified as minor: anemia
(hemoglobin < 100 g/l, hematocrit < 30%), post-
partum fever ( > 38C for at least 24 h), urinary tract
infection [leukocyturia, bacteriuria ( > 105 colony-
forming units/ml)], endometritis, wound infection, and
hematoma. Major complications were pneumonia,
thromboembolism, sepsis, peritonitis, diffuse intravas-
cular coagulation, subileus/ileus, and anemia requiring
blood transfusion (hemoglobin < 75 g/l, hematocrit <
25%). Complication rates and hospital stay were
compared between matched pairs. Surgeon experience
was documented as a potential confounding factor,
classified into the following levels: resident, fellow, and
attending surgeon.
Statistical analysis
Post-ECS complications in the infected group were
analyzed with respect to risk factors (Centers for Dis-
ease Control classification, viral load, CD4 lymphocyte
count, persistence of drug abuse). Fisher’s exact test
was used for categorical data, Student’s t test for nor-
mally distributed continuous data, and the Mann–
Whitney U test for ordinal data. All analyses were
performed using SPSS 11.5.1 and a P value < 0.05.
Based on a 1995 study in 156 women indicating a six-
fold higher postoperative complication rate in HIV-
infected women [4], a sample size of 140 women was
required for a statistical power of 80% (P = 0.05).
However, after interim analysis confirmed the
hypothesis of an increased postoperative complication
rate in HIV-seropositive women, we terminated the
study according to the protocol after including 106
women.
Results
Maternal age, gravidity, parity, and concomitant
disease were similar in the 53 matched pairs (Table 1),
as was operation time (Table 2). Current intravenous
drug abuse rates were 44.2% in the infected group
versus zero in the controls (P < 0.001). Immunological
status (CD4 lymphocyte count) and viral load data
were available in 94.3% (50/53) of infected patients
(Table 1). In 44.2% (23/53), infection was acquired by
intravenous drug use, and in 55.7% (29/53) by het-
erosexual contact; the source was unknown in the
remaining case. Mean gestational age at delivery was
shorter in the infected group [37.9 weeks (SD 1.97) vs.
39.0 weeks (SD 1.44) in the controls: P < 0.001].
Severe preeclampsia at 26 weeks in one infected case
and pregnancy-induced hypertension at 32 weeks in
another led to surgical delivery before 37 weeks of
gestation; in all other cases, ECS was performed after
37 weeks of gestation. No instance of neonatal HIV
infection occurred during the study. In the infected
group 86.8% (46/53) received antibiotic prophylaxis
versus 62.3% (33/53) of the controls (P < 0.04). ECS
was performed by residents in 22.6% (12/53) of the
infected group versus in 60.4% (32/53) of controls, by
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fellows in 37.7% (20/53) versus 11.3% (6/53), and
by attending surgeons in 39.6% (21/53) versus
28.3% (15/53), respectively (P < 0.001). Postoperative
recovery was uncomplicated in 41.5% (22/53) of the
HIV group versus 84.9% (45/53) of controls. Minor
complications were eightfold more frequent [relative
risk (RR): 7.94; 95% confidence interval (CI): 3.1–20.0;
P < 0.01]. Postoperative anemia occurred in 49%
(26/53) of the HIV group versus 9.4% (5/53) of controls
(RR: 9.24; CI: 3.2–26.9; P < 0.001). Mean estimated
intraoperative blood loss was higher in anemic than in
non-anemic HIV patients [652 ml (SD 113.6 ml) vs.
552 ml (SD 78.1 ml); P < 0.01]. Urinary tract infection
was more frequent in the HIV group [11.3% (6/53) vs.
3.7% (2/53); RR: 2.7; CI: 0.5–14.4; P < 0.05]. There
were two cases of fever in the HIV group versus none
in the controls, one postoperative hematoma per
group, and one wound dehiscence in the HIV group.
Major complications were recorded in 5.6% (3/53) of
the study group, versus none in the controls, including
two cases of pneumonia and one of thromboembolism,
P = 0.38. Hospital stay was significantly longer in the
HIV group (P < 0.001, Table 2).
Comment
Following several reports suggesting a significant in-
crease in post-ECS morbidity in HIV-infected women
with different population characteristics (Table 3) [4-6,
9-13], we found an eightfold increase in overall minor
complications, and a fivefold increase in postoperative
anemia. An important feature of our study is that viral
load data were available in 94% of our patients versus
in only 27% (26/97) in a comparable previous publi-
cation [6]. All our patients received HAART and over
60% had a non-detectable viral load: these rates are
also higher than those reported elsewhere. In addition,
58% received perioperative antibiotic prophylaxis.
Nevertheless, urinary tract infections were 2.7-fold
more frequent than in noninfected women, suggesting
an increased risk of postoperative infection in HIV-
seropositive patients. Therefore, we agree with Gru-
bert et al. [14] that the standard antibiotic prophylaxis
used in the nonimmunocompromised obstetric popu-
lation may be insufficient to prevent infections in HIV-
seropositive patients. Pairs were matched at each
center to reduce the bias of different operative and
postoperative schemes. In our study, ECS in the HIV
group was performed by the more experienced sur-
geons. Since this ought to have optimized postopera-
tive outcome, it further emphasizes the results. Our
finding of significantly higher blood loss in HIV-sero-
positive women contradicts two earlier studies [6, 15]
but confirms a recent report [10] which also showed
higher blood loss in previously anemic women. Our
study suggests that postoperative anemia tends to
result from markedly higher blood loss rather than from
slow postoperative bleeding or preoperative chronic
anemia [16]. This is in contrast to the hypothesis that
Table 2 HIV status and operation time, blood loss and hospital stay
HIV status P
Positive Negative
Operation time (min) 37.5 (18–55) 36.4 (17–57) 0.54*
Blood loss (ml, estimated) 601.9 (400–1,000) 479.3 (200–1,000) < 0.001*
Hospital stay (days) 9.4 (6–49) 6.5 (4–8) < 0.001**
Mean (range)
*t test, **Mann–Whitney U test
Table 1 Population demographic, obstetric and virologic char-
acteristics
Variable HIV status P
Positive Negative
Age (years) 32.55 (24–41) 31.00 (18–40) 0.10*
Parity 1.38 (0–4) 1.58 (1–4) 0.20**
Gravidity 2.12 (1–5) 2.04 (1–5) 0.59**
Gestational age
at delivery (week)
37.87 (26–40) 39.00 (32–42) 0.001**
Concomitant
diseasea [% (n/N)]
9.4 (5/53) 15 (8/53) 0.39***
CD4 count
> 500 mm–3 24
200–499 mm–3 21
< 200 mm–3 5
Unknown 3
Viral load
< 100 (log < 2) 36
100–10,000 (log 2–4) 11
10,000 (log > 4) 2
Unknown 3
Mean (range)
*t test, **Mann–Whitney U test,***Fisher’s exact test
aGestational diabetes, hepatitis C virus infection, epilepsy and
current intravenous drug abuse
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preoperative anemia due to antiretroviral therapy
accounts for the higher frequency of blood transfusion
[17]. Currently, the higher intraoperative blood loss
may be more significant than viral or drug-induced
anemia. Indeed, current reports suggest that anemia
may even improve with HAART [18]. The clinical
relevance of our finding lies in the previously docu-
mented association between anemia and reduced
survival [19, 20]. In addition, anemia may lower quality
of life in HIV-seropositive patients [21]. Overall, more
major complications were observed in the HIV-sero-
positive groups, reaching no statistical significance,
presumably due to the sample size. The increased
postoperative complication rate, which is also ex-
pressed in a marked prolongation of the hospital stay,
further worsens not only patient’s quality of life, but
also the financial burden on the healthcare system. A
potential weakness of our study was that it did not
achieve its intended statistical power. Further limita-
tions are the absence of preoperative hemoglobin lev-
els or platelet and coagulation factor data, which could
have had a bearing on intraoperative blood loss.
However, none of these factors is likely to have a sig-
nificant impact on the results, in particular, as our
primary focus was the association between HIV and
postoperative morbidity. In conclusion, our data indi-
cate that the current blanket recommendation of ECS
in HIV-seropositive patients requires review, espe-
cially in those with low/undetectable viral loads and
high CD4 counts, as a result of HAART.
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